Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer

Ann Transl Med. 2023 Mar 15;11(5):228. doi: 10.21037/atm-22-6266. Epub 2023 Jan 9.

Authors

Simone Nardin^{1

2}, Lucia Del Mastro^{1

2}

Affiliations

¹ U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
² Department of Internal Medicine and Medical Sciences (DiMI), School of Medicine, University of Genova, Genova, Italy.

No abstract available

Keywords: Breast cancer; Sacituzumab Govitecan (SG); Trastuzumab Deruxtecan; antibody-drug conjugate (ADC); hormone-receptor positive.

Publication types

Editorial
Comment